Logo image of OMER

OMEROS CORP (OMER) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OMER - US6821431029 - Common Stock

17.175 USD
+0.21 (+1.27%)
Last: 12/31/2025, 8:22:17 PM
17.95 USD
+0.77 (+4.51%)
After Hours: 12/31/2025, 8:22:17 PM
Fundamental Rating

0

Overall OMER gets a fundamental rating of 0 out of 10. We evaluated OMER against 191 industry peers in the Pharmaceuticals industry. OMER has a bad profitability rating. Also its financial health evaluation is rather negative. OMER is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

OMER had negative earnings in the past year.
In the past year OMER has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: OMER reported negative net income in multiple years.
OMER had negative operating cash flow in 4 of the past 5 years.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.24%, OMER is doing worse than 68.59% of the companies in the same industry.
Industry RankSector Rank
ROA -65.24%
ROE N/A
ROIC N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, OMER has less shares outstanding
Compared to 5 years ago, OMER has more shares outstanding
Compared to 1 year ago, OMER has a worse debt to assets ratio.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -8.10, we must say that OMER is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.10, OMER is not doing good in the industry: 68.59% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.1
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.89 indicates that OMER may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.89, OMER is doing worse than 86.39% of the companies in the same industry.
OMER has a Quick Ratio of 0.89. This is a bad value and indicates that OMER is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of OMER (0.89) is worse than 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

1

3. Growth

3.1 Past

OMER shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.55%, which is quite good.
EPS 1Y (TTM)12.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OMER is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.5%
EPS Next 2Y41.75%
EPS Next 3Y28.5%
EPS Next 5Y29.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 687.27, which means the current valuation is very expensive for OMER.
Based on the Price/Forward Earnings ratio, OMER is valued a bit cheaper than the industry average as 66.49% of the companies are valued more expensively.
OMER's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.13.
Industry RankSector Rank
PE N/A
Fwd PE 687.27
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
OMER's earnings are expected to grow with 28.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.75%
EPS Next 3Y28.5%

0

5. Dividend

5.1 Amount

OMER does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OMEROS CORP

NASDAQ:OMER (12/31/2025, 8:22:17 PM)

After market: 17.95 +0.77 (+4.51%)

17.175

+0.21 (+1.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners46.69%
Inst Owner Change12.65%
Ins Owners2.77%
Ins Owner Change-29.99%
Market Cap1.22B
Revenue(TTM)N/A
Net Income(TTM)-121.16M
Analysts80
Price Target34.34 (99.94%)
Short Float %20.2%
Short Ratio5.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.4%
Min EPS beat(2)-3.55%
Max EPS beat(2)12.36%
EPS beat(4)2
Avg EPS beat(4)10.09%
Min EPS beat(4)-3.55%
Max EPS beat(4)31.91%
EPS beat(8)5
Avg EPS beat(8)18.23%
EPS beat(12)8
Avg EPS beat(12)50.79%
EPS beat(16)11
Avg EPS beat(16)44.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.51%
EPS NY rev (1m)-4.48%
EPS NY rev (3m)-4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 687.27
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.02
EYN/A
EPS(NY)0.02
Fwd EY0.15%
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS-3.11
TBVpS-3.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -8.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.18%
Cap/Depr(5y)22.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.07%
EPS Next Y25.5%
EPS Next 2Y41.75%
EPS Next 3Y28.5%
EPS Next 5Y29.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-225.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-225.02%
OCF growth 3YN/A
OCF growth 5YN/A

OMEROS CORP / OMER FAQ

What is the ChartMill fundamental rating of OMEROS CORP (OMER) stock?

ChartMill assigns a fundamental rating of 0 / 10 to OMER.


What is the valuation status of OMEROS CORP (OMER) stock?

ChartMill assigns a valuation rating of 1 / 10 to OMEROS CORP (OMER). This can be considered as Overvalued.


Can you provide the profitability details for OMEROS CORP?

OMEROS CORP (OMER) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for OMER stock?

The Earnings per Share (EPS) of OMEROS CORP (OMER) is expected to grow by 25.5% in the next year.